53
Research Trials
20
Peer-reviewed publications
16
Clinical Conditions
At CHEST 2025, held in Chicago, Illinois, Laurie Slovarp, PhD, CCC-SLP, professor at the University of Montana and certified speech pathologist, presented a poster on the development of a digital therapeutic designed to improve access to behavioral cough suppression therapy for patients with refractory chronic cough.
A large-scale trial examining the effect of azithromycin on the relationship between oesophageal function and cough as evaluated by Hyfe's cough monitoring technology in respiratory disease is feasible and acceptable to patients.
This study used Hyfe's wearable cough monitor during a 7-day run in, 28-day treatment, and 14-day follow-up period in patients with chronic bronchitis.
Periods of intense coughing (termed bouts, epochs or bursts) are particularly problematic for some coughers and may not be reflected by simply counting the number of coughs per day. This study explored how varying the definition of bouts yield different impressions of cough severity.
21.10.2025
Despite recent advances, there are no FDA-approved drugs for refractory/unexplained chronic cough (RCC/UCC). Numerous studies have demonstrated efficacy of cough suppression treatment (CST) by specialty-trained speech-language pathologists (SLPs). While recommended in consensus statements, there is a significant shortage of specialized SLPs to treat the estimated 5-7 million cases of RCC/UCC in the US. We have integrated essential components of CST within the CoughPro cough monitoring application with the purpose of testing proof of concept for a CST digital therapeutic.
